BIOMAT Database Logo BIOMAT Database Logo

Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. 2005

M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
Department of Biochemistry, Hospital General of Móstoles, Móstoles, Madrid, Spain. mgg10167@teleline.es

BACKGROUND Resistance to insulin and secondary hyperinsulinemia seem to be the putative link between morbid obesity (MO) and hypertensive disease (HD). Adipose tissue can secrete leptin and angiotensinogen, among other substances. Leptin activates the sympathetic nervous system, leading to HD. Angiotensinogen is a substrate for renin, therefore taking part in the renin-angiotensin-aldosterone axis and the regulation of blood pressure. In MO, both hypertrophy and hyperplasia of the adipocytes lead to an increase in the secretion of both substances, leading to loss of the equilibrium between the levels of both hormones. The aim of the present study was to evaluate these abnormalities and their potential reversibility following bariatric surgery. METHODS Data from 100 patients with MO was retrospectively evaluated. Anthropometric data, the plasma renin activity (PRA), plasma levels of aldosterone, ACE, potassium and sodium were collected both prior to surgery and 6, 12, 24 and 36 months after surgery. RESULTS The waist-hip ratio (WHR) before surgery allowed classification of our patients in two groups: central obesity (WHR > or =0.90 in men and > or =0.85 in women); peripheral obesity (WHR <0.90 in men and <0.85 in women). In patients with central obesity, high levels of PRA, aldosterone and ACE with sodium retention and potassium loss and high insulin levels, were found. These changes were not found in patients with peripheral obesity. After gastric bypass, these abnormalities tended to disappear, mainly in the first 6 months. CONCLUSIONS The reduction of BMI and WHR after gastric bypass confirmed this operation to be effective against MO. The high basal levels of insulin and the high rate of HD and diabetes in patients with central obesity seem to indicate that they suffer a metabolic syndrome with significant hormonal imbalances and sodium retention. Patients with peripheral obesity only showed a peripheral resistance against insulin, probably with a shorter duration of the hormonal action, but they did not show hormonal abnormalities or sodium retention. After gastric bypass these abnormal hormone levels tended to normalize.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009767 Obesity, Morbid The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2. Morbid Obesity,Obesity, Severe,Morbid Obesities,Obesities, Morbid,Obesities, Severe,Severe Obesities,Severe Obesity
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
Anesthetics and the renin--angiotensin--aldosterone axis.
June 1978, Anesthesiology,
M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
The renin, angiotensin, aldosterone, and obesity connection.
September 2010, Journal of molecular medicine (Berlin, Germany),
M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
Obesity and the renin- angiotensin-aldosterone system.
March 2006, Expert review of endocrinology & metabolism,
M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
[Physiology of the renin-angiotensin-aldosterone axis].
January 1977, Revista clinica espanola,
M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
[The renin-angiotensin-aldosterone system and hypertensive syndromes].
May 1978, La Revue du praticien,
M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
Plasma renin, renin substrate, angiotensin II, and aldosterone in hypertensive disease of pregnancy.
February 1973, Lancet (London, England),
M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
[Renin-angiotensin-aldosterone system in hypertensive conditions].
October 1967, Deutsche medizinische Wochenschrift (1946),
M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
Targeting the Renin-Angiotensin-Aldosterone System in Obesity.
July 2020, Arquivos brasileiros de cardiologia,
M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system.
January 2004, The Medical clinics of North America,
M Ruano, and V Silvestre, and R Castro, and M C G García-Lescún, and A Rodríguez, and A Marco, and G García-Blanch
Liquorice toxicity and the renin-angiotensin-aldosterone axis in man.
January 1977, British medical journal,
Copied contents to your clipboard!